Herpes zoster burden in patients with asthma: real-world incidence, healthcare resource utilisation and cost

被引:0
|
作者
Singer, David [1 ]
Thompson-Leduc, Philippe [2 ]
Ma, Siyu [3 ]
Gupta, Deepshekhar [4 ]
Cheng, Wendy Y. [5 ]
Muthukumar, Aruna [4 ]
Devine, Francesca [6 ]
Sundar, Manasvi [7 ]
Bogart, Michael [8 ,9 ]
Hagopian, Ella [5 ]
Poston, Sara [1 ]
Duh, Mei Sheng [5 ]
Oppenheimer, John J. [10 ]
机构
[1] GSK, Philadelphia, PA 19104 USA
[2] Anal Grp Inc, Montreal, PQ, Canada
[3] GSK, Tufts Med Ctr, Boston, MA USA
[4] Anal Grp Inc, Menlo Pk, CA USA
[5] Anal Grp Inc, Boston, MA USA
[6] Anal Grp Inc, New York, NY USA
[7] Anal Grp Inc, Los Angeles, CA USA
[8] GSK, Res Triangle Pk, NC USA
[9] Gilead Sci, Foster City, CA USA
[10] Rutgers New Jersey Med Sch, Newark, NJ USA
关键词
Asthma; Asthma Epidemiology; Health Economist; Viral infection; SUBUNIT VACCINE; ADULTS; RISK; EFFICACY; SCORE; US;
D O I
10.1136/bmjresp-2023-002130
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background Herpes zoster (HZ) is a painful condition caused by reactivation of the varicella-zoster virus. The objectives of this study were to compare HZ incidence in adults with asthma versus adults without asthma and to compare healthcare resource use as well as direct costs in adults with HZ and asthma versus adults with asthma alone in the USA.Methods This retrospective longitudinal cohort study included adults aged >= 18 years across the USA. Patients were identified from Optum's deidentified Clinformatics Data Mart Database, an administrative claims database, between 1 October 2015 and 28 February 2020, including commercially insured and Medicare Advantage with part D beneficiaries. Cohorts of patients with and without asthma, and separate cohorts of patients with asthma and HZ and with asthma but not HZ, were identified using International Classification of Diseases 10th Revision, Clinical Modification codes. HZ incidence, healthcare resource use and costs were compared, adjusting for baseline characteristics, between the relevant cohorts using generalised linear models.Results HZ incidence was higher in patients with asthma (11.59 per 1000 person-years) than patients without asthma (7.16 per 1000 person-years). The adjusted incidence rate ratio (aIRR) for HZ in patients with asthma, compared with patients without asthma, was 1.34 (95% CI 1.32 to 1.37). Over 12 months of follow-up, patients with asthma and HZ had more inpatient stays (aIRR 1.11; 95% CI 1.02 to 1.21), emergency department visits (aIRR 1.26; 95% CI 1.18 to 1.34) and outpatient visits (aIRR 1.19; 95% CI 1.16 to 1.22), and direct healthcare costs that were US dollars ($) 3058 (95% CI $1671 to $4492) higher than patients with asthma without HZ.Conclusion Patients with asthma had a higher incidence of HZ than those without asthma, and among patients with asthma HZ added to their healthcare resource use and costs.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Incidence of Herpes Zoster in Patients with Asthma Compared to Patients without Asthma: A Retrospective Database Study
    Singer, David
    Thompson-Leduc, Philippe
    Gupta, Deepshekhar
    Ma, Siyu
    Cheng, Wendy
    Sundar, Manasvi
    Hagopian, Ella
    Duh, Mei Sheng
    Oppenheimer, John
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 151 (02) : AB227 - AB227
  • [32] Hospital resource utilisation from HPV-related diseases in England: a real-world cost analysis
    Fabiano, G.
    Marcellusi, A.
    Mennini, F. S.
    Sciattella, P.
    Favato, G.
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2023, 24 (01): : 75 - 80
  • [33] Hospital resource utilisation from HPV-related diseases in England: a real-world cost analysis
    G. Fabiano
    A. Marcellusi
    F. S. Mennini
    P. Sciattella
    G. Favato
    The European Journal of Health Economics, 2023, 24 : 75 - 80
  • [34] Dupilumab Real-world Effectiveness (RWE) in Reducing Healthcare Resource Utilization Among Moderate-to-Severe Asthma Patients
    Modena, B. D.
    Pawar, A.
    Blaiss, M. S.
    Khan, A.
    Gomez, L. De Prado
    Zhang, Y.
    Radwan, A.
    Jacob-Nara, J. A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [35] Real-world effectiveness (RWE) of dupilumab in reducing healthcare resource utilization among moderate-to-severe asthma patients
    Pawar, A.
    Blaiss, M. S.
    Modena, B. D.
    Khan, A. H.
    Gomez, L. De Prado
    Zhang, Y.
    Siddiqui, S.
    Jacob-Nara, J. A.
    Gomez, L. De Prado
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [36] REAL-WORLD HEALTHCARE RESOURCE UTILIZATION AND ASSOCIATED COSTS IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS
    Tencer, T.
    Xia, Q.
    Jobson, G.
    Qian, E.
    Dellon, E. S.
    VALUE IN HEALTH, 2022, 25 (07) : S432 - S432
  • [37] Healthcare Utilization and Cost Burden in Patients with Severe Asthma
    Nagar, S. P.
    Stanford, R. H.
    White, J.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2011, 127 (02) : AB73 - AB73
  • [38] Real-World Evidence on Rates of MS Relapse and Healthcare Resource Utilisation Following COVID-19 Vaccination
    Kuranz, S.
    Landsman-Blumberg, P.
    Wong, S.
    Tundia, N.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 287 - 288
  • [39] Real-world impact of flaring on patient-reported outcomes and healthcare resource utilisation in systemic lupus erythematosus
    Costenbader, K. H.
    Hoskin, B.
    Atkinson, C.
    Bell, D.
    Pike, J.
    Lofland, J. H.
    Berry, P.
    Karyekar, C. S.
    Touma, Z.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2022, 40 (11) : 2023 - 2031
  • [40] CLINICAL AND ECONOMIC BURDEN OF HERPES ZOSTER IN PATIENTS WITH ASTHMA: A RETROSPECTIVE COHORT STUDY
    Singer, D.
    Thompson-Leduc, P.
    Ma, S.
    Gupta, D.
    Cheng, W.
    Duh, M.
    Bogart, M.
    Oppenheimer, J.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2022, 129 : S43 - S44